All Photos(1)

Documents

L0702000

Lisinopril dihydrate

Name: Lisinopril dihydrate
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Lisinopril, (S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₁H₃₁O₅N₃ · 2H₂O

CAS Number:

83915-83-7

Molecular Weight:

441.52

MDL number:

MFCD01698825

UNSPSC Code:

41116107

PubChem Substance ID:

329817371

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

lisinopril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lisinopril dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1368610

BP695

Lisinopril dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

GHS08

Signal Word

Danger

Hazard Statements

H360D,H373

Precautionary Statements

P202 - P260 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 1A - STOT RE 2

Target Organs

Kidney

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Non-destructive dose verification of two drugs within 3D printed polyprintlets.

Sarah J Trenfield et al.

International journal of pharmaceutics, 577, 119066-119066 (2020-01-27)

Three-dimensional printing (3DP) is a revolutionary technology in pharmaceuticals, enabling the personalisation of flexible-dose drug products and 3D printed polypills (polyprintlets). A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying

Silibinin enhances anti-renal fibrosis effect of MK-521 via downregulation of TGF-β signaling pathway.

Zhongchao Ma et al.

Human cell, 33(2), 330-336 (2020-01-19)

Renal fibrosis is a common characteristic of chronic kidney disease (CKD), and it can lead to end-stage renal disease. It has been reported that silibinin or lisinopril (MK-521) can inhibit the progression of renal fibrosis. However, the effect of combination

Green micellar HPLC analysis of three angiotensin-converting enzyme inhibitors in their mixtures with hydrochlorothiazide and modeling of their retention behavior by fitting to Foley's model.

Manal Eid et al.

Journal of separation science, 40(18), 3646-3654 (2017-07-20)

We present an environmentally friendly method for the analysis of three angiotensin-converting enzyme inhibitors and hydrochlorothiazide simultaneously using a green micellar eluent for the first time. The chromatographic separation of enalapril maleate, lisinopril dihydrate, benazepril hydrochloride, and hydrochlorothiazide was implemented

Lisinopril: a review of its use in congestive heart failure.

K Simpson et al.

Drugs, 59(5), 1149-1167 (2000-06-14)

The ACE inhibitor lisinopril is a lysine derivative of enalaprilat, the active metabolite of enalapril. In patients with heart failure, maximum pharmacodynamic effects are produced 6 to 8 hours after administration of the drug and persist for 12 to 24

Lisinopril-induced isolated visceral angioedema: review of ACE-inhibitor-induced small bowel angioedema.

M F Abdelmalek et al.

Digestive diseases and sciences, 42(4), 847-850 (1997-04-01)

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service